{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:07:26Z","timestamp":1790676446432,"version":"4.1.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","award":["RGP.1\/330\/42"],"award-info":[{"award-number":["RGP.1\/330\/42"]}],"id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Celecoxib (CLB) is a highly hydrophobic selective <jats:italic>cyclo-oxygenase<\/jats:italic> inhibitor with high plasma protein binding and undergoes extensive hepatic metabolism. CLB is highly effective in the treatment of osteo and rheumatoid arthritis as first line therapy but produces severe gastro-intestinal toxicities and cardiovascular side effects. In this research, stealth liposomes of CLB were developed with the intention to reduce the side effects and increase the accumulation of drug in the sites of inflammation. Stealth liposomes were prepared by thin film hydration technique using distearoylphosphatidylcholine and PE-PEG 2000 with variable amounts of cholesterol and characterized. The effects of various lipids such as hydrogenated soy phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoylphosphatidylcholine and cholesterol content on % drug encapsulation was investigated. The optimized stealth liposomes were characterized by FT-IR and DSC for possible drug excipients interaction. Pharmacokinetics, pharmacodynamics and biodistribution studies were carried out for the stealth liposomes. The results revealed that the stealth liposomes reduced the inflammation to the larger magnitude and have also sustained the magnitude when compared to free drug along with maximum analgesic response. Higher elimination half-life, AUC, MRT and lowered clearance rate denotes the extended bioavailability of the drug in blood. Biodistribution studies revealed that stealth liposomes extend the circulation time of liposomes in blood by decreasing opsonisation and be less concentrated in kidney, thereby reducing the toxicities to RES and renal organs and facilitate the drug accumulation in the area of inflammation. Our results indicated that CLB, without the requirement of modifications to enhance solubilisation, can be encapsulated and released from liposomal formulations. This new-fangled drug delivery approach may be used to circumvent the low bioavailability and toxic side effects of oral CLB formulations.<\/jats:p>","DOI":"10.1371\/journal.pone.0264518","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T17:51:08Z","timestamp":1650995468000},"page":"e0264518","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Development of stealth liposomal formulation of celecoxib: In vitro and in vivo evaluation"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-8585","authenticated-orcid":true,"given":"M. Yasmin","family":"Begum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2333-0817","authenticated-orcid":true,"given":"Riyaz Ali","family":"M. Osmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-4757","authenticated-orcid":true,"given":"Ali","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Ghazwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umme","family":"Hani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hissana","family":"Ather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhtar","family":"Atiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Rahamathulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Siddiqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"pone.0264518.ref001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1477-3155-6-8","article-title":"Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion","volume":"6","author":"F Shakeel","year":"2008","journal-title":"J Nanobiotechnol"},{"key":"pone.0264518.ref002","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J","article-title":"Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects","volume":"41","author":"LE Simon","year":"1998","journal-title":"Arthritis Rheum"},{"key":"pone.0264518.ref003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jddst.2015.02.001","article-title":"Calcium alginate multi-unit oral dosage form for delayed release of celecoxib","volume":"26","author":"L Segale","year":"2015","journal-title":"J Drug Deliv Sci Technol"},{"key":"pone.0264518.ref004","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ejmech.2005.03.001","article-title":"Preparation of celecoxib-dimethyl-\u00df- cyclodextrin inclusion complex: characterization and in vitro permeation study","volume":"40","author":"C Anna","year":"2005","journal-title":"Eur J Med Chem"},{"key":"pone.0264518.ref005","first-page":"638","article-title":"Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption","volume":"297","author":"SK Paulson","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"pone.0264518.ref006","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1081\/DDC-120021773","article-title":"Preparation and characterization of glassy celecoxib","volume":"29","author":"AR Paradkar","year":"2003","journal-title":"Drug Dev Ind Pharm"},{"issue":"4","key":"pone.0264518.ref007","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2165\/00003495-200059040-00017","article-title":"Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain","volume":"59","author":"D Clemett","year":"2000","journal-title":"Drugs"},{"key":"pone.0264518.ref008","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/10717540601098740","article-title":"Multivesicular liposomes bearing celecoxib \u03b2 \u2013cyclodextrin complex for transdermal drug delivery","volume":"14","author":"SK Jain","year":"2007","journal-title":"Drug Deliv"},{"key":"pone.0264518.ref009","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003088-200038030-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo- oxygenase-2-inhibior","volume":"38","author":"NM Davies","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"pone.0264518.ref010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.atherosclerosis.2004.10.001","article-title":"Sulfone cox-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparision to sulfonamide cox-2 inhibitors and NSAIDS","volume":"177","author":"MF Walter","year":"2004","journal-title":"Atherosclerosis"},{"key":"pone.0264518.ref011","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/(SICI)1099-081X(199909)20:6<293::AID-BDD188>3.0.CO;2-X","article-title":"Plasmaprotein binding of celecoxib in mice, rat, rabbit, dog and human","volume":"20","author":"SK Paulson","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"pone.0264518.ref012","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"SD Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"pone.0264518.ref013","first-page":"317","article-title":"Lamivudine liposomes for transdermal delivery-formulation, characterization, stability, in vitro evaluation","volume":"1","author":"RS Pai","year":"2009","journal-title":"Int J Pharm Sci Nanotechnol"},{"key":"pone.0264518.ref014","first-page":"297","article-title":"Stealth Liposomes: review of basic science, rationale and clinical applications, existing and potential","volume":"3","author":"ML Immordino","year":"2006","journal-title":"Int J Nanomedicine"},{"key":"pone.0264518.ref015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jddst.2016.02.009","article-title":"Trans resveratrol loaded DSPE PEG 2000 coated liposomes: An evidence for prolonged systemic circulation and passive brain targeting","volume":"33","author":"MR Vijayakumar","year":"2016","journal-title":"J Drug Deliv Sci Technol"},{"key":"pone.0264518.ref016","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpharm.2004.07.010","article-title":"Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability","volume":"285","author":"AR Mohammed","year":"2004","journal-title":"Int J Pharm"},{"key":"pone.0264518.ref017","doi-asserted-by":"crossref","first-page":"100288","DOI":"10.1016\/j.nanoso.2019.100288","article-title":"Synthesis and characterization of celecoxib loaded PEGylated liposome nanoparticles for biomedical applications","volume":"18","author":"V Dave","year":"2019","journal-title":"Nano-Struct Nano-Objects"},{"key":"pone.0264518.ref018","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4103\/0250-474X.34548","article-title":"An approach to minimize pseudomembranous colitis caused by clindamycin through liposomal formulation","volume":"69","author":"MV Ramana","year":"2007","journal-title":"Indian J Pharm Sci"},{"issue":"2","key":"pone.0264518.ref019","first-page":"252","article-title":"Tamoxifen in topical liposomes: development, characterization and in vitro evaluation","volume":"7","author":"R Kumar","year":"2004","journal-title":"J Pharm Pharmaceut Sci"},{"issue":"1","key":"pone.0264518.ref020","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1208\/pt0801001","article-title":"Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies","volume":"8","author":"RM Hathout","year":"2007","journal-title":"AAPS Pharm Sci Tech"},{"key":"pone.0264518.ref021","first-page":"507","article-title":"Tamoxifen citrate encapsulated sustained release liposomes: preparation and evaluation of physico chemical properties","volume":"76","author":"L Buddhadev","year":"2010","journal-title":"Sci pharm"},{"key":"pone.0264518.ref022","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijpharm.2003.10.031","article-title":"Stability and transdermal absorption of topical amphotericin B liposome formulations","volume":"270","author":"A Manosroi","year":"2004","journal-title":"Int J Pharm"},{"key":"pone.0264518.ref023","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejps.2006.03.008","article-title":"Drug permeability across a phospholipid vesicle based barrier: 2. Characterization of barrier structure, storage stabity and stabity towords pH changes","volume":"28","author":"E Goril","year":"2006","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"pone.0264518.ref024","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/0250-474X.65014","article-title":"Design and evaluation of liposomal formulation of pilocarpine nitrate","volume":"72","author":"S Rathode","year":"2010","journal-title":"Indian J Pharm Sci"},{"issue":"1","key":"pone.0264518.ref025","first-page":"1766","article-title":"Ketorolac loaded liposomes: Development, characterization and in vitro evaluation","volume":"4","author":"MY Begum","year":"2011","journal-title":"Res J Pharm Technol"},{"key":"pone.0264518.ref026","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","article-title":"Modeling and comparison of dissolution profiles","volume":"13","author":"P Costa","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"pone.0264518.ref027","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0378-5173(99)00029-0","article-title":"Preparation and evaluation of flurbiprofen-loaded microemulsion for parenteral delivery","volume":"181","author":"KM Park","year":"1999","journal-title":"Int J Pharm"},{"key":"pone.0264518.ref028","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1208\/s12249-009-9364-5","article-title":"In vitro and in vivo evaluation of proniosomes containing celecoxib for oral Administration","volume":"11","author":"M. Nasr","year":"2010","journal-title":"AAPS PharmSci Tech"},{"key":"pone.0264518.ref029","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/jps.24022","article-title":"Aerosol-stable peptide-coated liposome nanoparticles: a proof-of-concept study with opioid fentanyl in enhancing analgesic effects and reducing plasma drug exposure","volume":"103","author":"JD Hoekman","year":"2014","journal-title":"J Pharm Sci"},{"issue":"1","key":"pone.0264518.ref030","first-page":"136","article-title":"Evaluation of skin permeation and anti-inflammatory and analgesic effects of new naproxen microemulsion formulations","volume":"416","author":"NO Ustundag","year":"2011","journal-title":"Int J Pharm"},{"issue":"2","key":"pone.0264518.ref031","first-page":"373","article-title":"Myo cardial adjuant periarthritis in rodents and its modification by anti-inflammatory agents","volume":"153","author":"NL Graeme","year":"1966","journal-title":"J Pharmacol Exp Ther"},{"key":"pone.0264518.ref032","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejpb.2004.06.009","article-title":"Development and characterization of a novel Cremophor\u00ae EL free liposome-based paclitaxel (LEP- ETU) formulation","volume":"59","author":"JA Zhang","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"key":"pone.0264518.ref033","first-page":"252","article-title":"Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation","volume":"7","author":"A Bhatia","year":"2004","journal-title":"J Pharm Pharm Sci"},{"key":"pone.0264518.ref034","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1021\/bi00190a022","article-title":"Hydrophobic barriers of bilayer-membranes formed by reduction of water penetration by alkyl chain unsaturation and cholesterol","volume":"33","author":"WK Subczynski","year":"1994","journal-title":"Biochemistry"},{"key":"pone.0264518.ref035","first-page":"01","article-title":"Development and optimization of stealth liposomal system for enhanced in vitro cytotoxic effect of quercetin","volume":"55","author":"LA Saraswati","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"pone.0264518.ref036","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/08982100802673940","article-title":"The encapsulation and release of guanosine from PEGylated liposomes","volume":"19","author":"Y Er","year":"2009","journal-title":"J Lipos Res"},{"issue":"16","key":"pone.0264518.ref037","doi-asserted-by":"crossref","first-page":"12913","DOI":"10.1039\/C5RA22672D","article-title":"Intra-articular delivery of a methotrexate loaded nanostructured lipid carrier based smart gel for effective treatment of rheumatic diseases","volume":"6","author":"CG Shinde","year":"2016","journal-title":"RSC Adv"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T17:51:52Z","timestamp":1650995512000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264518"}},"subtitle":[],"editor":[{"given":"Muhammad","family":"Hanif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0264518","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]}}}